Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hongyu Yang, Yu Zhang, Dan Su, Yue Chen
Summary: This article presents a case of castration-resistant prostate cancer with multiple bone metastases, where remission of clinical symptoms and imaging lesions were observed after 4 cycles of Ac-225-PSMA-617 therapy, with no observable adverse effects.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Oncology
Mashari Alzahrani, Mark Clemons, Marta Sienkiewicz, Noa Shani Shrem, Sharon F. McGee, Lisa Vandermeer, Sandeep Sehdev, Marie France Savard, Arif Awan, Christina Canil, Brian Hutton, Gregory Pond, Deanna Saunders, Terry Ng
Summary: The optimal use of bone-modifying agent therapy in patients with bone metastases from breast and castrate-resistant prostate cancer is evolving. Study found misconceptions about the benefits of BMAs among patients, indicating a need for more patient education. Most patients were interested in further de-escalation of BMA therapy after 2 years of prior treatment.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Oncology
Mark Clemons, Michael Ong, Carol Stober, Scott Ernst, Christopher Booth, Christina Canil, Mihaela Mates, Andrew Robinson, Phillip Blanchette, Anil Abraham Joy, John Hilton, Olexiy Aseyev, Gregory Pond, Ahwon Jeong, Brian Hutton, Sasha Mazzarello, Lisa Vandermeer, Igal Kushnir, Dean Fergusson
Summary: The study compared the efficacy of bone-targeted agents (BTAs) given every 4 weeks versus 12 weeks in patients with bone metastases from breast or castration-resistant prostate cancer. The results showed no significant difference in health-related quality of life, pain, global health status, rates of symptomatic skeletal events, and time to symptomatic skeletal events between the two dosing regimens. The findings suggest that de-escalation of commonly used BTAs is a viable treatment option.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Chemistry, Medicinal
Yujie Huang, You Zhai, Meijia Wu, Chengdong Chang, Jindan Luo, Dongsheng Hong, Qingwei Zhao, Yao Dai, Jian Liu
Summary: This study investigated the role of mTORC2 signaling in docetaxel-resistant prostate cells to find potential methods for clinical treatment. The expression of mTORC2 is crucial for docetaxel drug resistance in prostate cells. The mTORC1/2 inhibitor AZD8055 disrupts mTORC2 kinase activity more significantly than the mTORC1 inhibitor Rapamycin, leading to decreased docetaxel-mediated resistance. Therefore, reversing docetaxel resistance may become a therapeutic option for the treatment of metastatic castration-resistant prostate cancer patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Biology
Kevin J. Tu, Sanjit K. Roy, Zachery Keepers, Manas R. Gartia, Hem D. Shukla, Nrusingh C. Biswal
Summary: The study investigates the effectiveness and molecular characteristics of the combination therapy of Docetaxel (DXL) and radiation in vitro. The results suggest that DXL sensitizes castration-resistant prostate cancer (CRPC) cells to radiation by downregulating CAV-1.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Maria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, Chiara Casadei, Alessandra Virga, Paola Ulivi, Sara Bleve, Nicole Brighi, Giorgia Ravaglia, Francesco Pantano, Vincenza Conteduca, Daniele Santini, Ugo De Giorgi
Summary: This study evaluated the prevalence of DNA damage repair (DDR) gene mutations in castration-resistant prostate cancer (CRPC) patients and their impact on clinical outcomes related to bone metastases. The results showed that DDR mutations were associated with larger bone metastases volume, but did not affect skeletal-related events incidence and time to onset.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Summary: This case report highlights the potential effectiveness and safety of a second docetaxel rechallenge as a later-line treatment strategy for patients with mCRPC who are concerned about the high costs of multigene molecular testing and PARP inhibitors, as well as repeated prostate needle biopsy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Atefeh Deris, Mahdi Sohrabi-Haghighat
Summary: Patients with mCRPC are classified into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. Drug-resistant cells may hinder successful outcomes in the latter two groups. To overcome this challenge, a combination of Docetaxel and Abiraterone is proposed to control both the overall cancer cell population and the drug-resistant subpopulation. Evolutionary Game Theory (EGT) is used as a mathematical modeling approach to study the competition and evolution of mCRPC cancer phenotypes.
Article
Oncology
Masanori Noguchi, Kiyohide Fujimoto, Gaku Arai, Hiroji Uemura, Katsuyoshi Hashine, Hiroaki Matsumoto, Satoshi Fukasawa, Yasuo Kohjimoto, Hideomi Nakatsu, Atsushi Takenaka, Masato Fujisawa, Hirotsugu Uemura, Seiji Naito, Shin Egawa, Hiroyuki Fujimoto, Shiro Hinotsu, Kyogo Itoh
Summary: This study investigated the impact of personalized peptide vaccination (PPV) on overall survival (OS) in HLA-A24-positive patients with castration-resistant prostate cancer (CRPC) who failed docetaxel chemotherapy. The results showed that PPV did not prolong OS overall, but subgroup analysis revealed survival benefits in patients with a lower proportion of neutrophils or a higher proportion of lymphocytes at baseline.
Article
Urology & Nephrology
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, Youssef Tazi, Philippe Beuzeboc, Marine Gross-Goupil, Emmanuelle Bompas, Florence Joly, Charlotte Greilsamer, Thierry Nguyen Tan Hon, Philippe Barthelemy, Stephane Culine, Jean Francois Berdah, Mathilde Deblock, Raffaele Ratta, Aude Flechon, Caroline Cheneau, Aline Maillard, Geraldine Martineau, Isabelle Borget, Karim Fizazi
Summary: The preference for cabazitaxel over docetaxel among chemotherapy-naive men with mCRPC is mainly driven by reduced fatigue and improved quality of life.
Review
Oncology
Giandomenico Roviello, Martina Catalano, Carlotta Ottanelli, Roberta Giorgione, Virginia Rossi, Elisabetta Gambale, Chiara Casadei, Ugo De Giorgi, Lorenzo Antonuzzo
Summary: The treatment landscape for metastatic castration-resistant prostate cancer has evolved with several drug classes available. Lack of validated predictive biomarkers makes therapeutic choice difficult. The location of metastatic site may be a valid criterion for selecting among treatment options.
Article
Oncology
Xiang Cai, Xi Duan, Tielong Tang, Shu Cui, Tao Wu
Summary: This study investigated the mechanism of JMJD2A in regulating cytoskeleton remodeling in docetaxel-resistant castration-resistant prostate cancer cells. The results showed that JMJD2A regulates cytoskeleton remodeling through the miR-34a/STMN1/beta 3-Tubulin axis. Overexpression of miR-34a resulted in downregulation of STMN1 and upregulation of beta 3-Tubulin, leading to disruption of the microtubule network, inhibition of cancer cell proliferation, cell cycle arrest, and increased apoptosis.
Article
Oncology
Simon J. Crabb, Gareth Griffiths, Ellice Marwood, Denise Dunkley, Nichola Downs, Karen Martin, Michelle Light, Josh Northey, Sam Wilding, Amy Whitehead, Emily Shaw, Alison J. Birtle, Amit Bahl, Tony Elliott, Charlotte Westbury, Santhanam Sundar, Angus Robinson, Satinder Jagdev, Satish Kumar, Claire Rooney, Carolina Salinas-Souza, Christine Stephens, Vincent Khoo, Robert J. Jones
Summary: Capivasertib as a pan-AKT inhibitor did not prolong cPFS in mCRPC patients, but the observed OS result shows potential and requires prospective validation in future studies.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske, Lothar Weissbach
Summary: This study examined real-world haematological toxicity, overall survival, and treatment characteristics of docetaxel and cabazitaxel chemotherapy in mCRPC patients. The findings suggest that cabazitaxel treatment poses higher risk of haematological toxicities and shorter survival time, emphasizing the importance of strict indications when using cabazitaxel in mCRPC patients.